New Study Reveals B Cells Play a Larger Role in Type 1 Diabetes Than Previously Understood

Scientists have long known that B cells—immune cells that make antibodies—play a role in Type 1 diabetes. The traditional understanding was that B cells trigger T cells to attack insulin-producing beta cells in the pancreas. But new research from Vanderbilt Health reveals B cells are doing additional damage.

A study published in Diabetes, the journal of the American Diabetes Association, shows that B cells also interfere with regulatory T cells (Tregs). Tregs are like peacekeepers of the immune system—they calm immune attacks and help protect the pancreas. When B cells weaken these peacekeepers, the damage to beta cells accelerates.

"This finding shifts our understanding of B lymphocytes from serving as simple accomplices in the development of Type 1 diabetes to more active saboteurs," said Dr. Daniel Moore, the study's lead author and an associate professor of Pediatrics at Vanderbilt Health.

Researchers studied mouse models that lacked B cells entirely. In these mice, regulatory T cells were significantly stronger and worked more effectively at protecting the body. When the team transplanted insulin-producing pancreatic tissue into these B-cell-free mice, the transplanted tissue survived much longer than expected.

This comparison demonstrated the importance of B cells in weakening the immune system's natural defenses. The stronger Tregs in B-cell-free mice were better able to prevent immune attacks on both native and transplanted beta cells.

Understanding B cells' dual role opens new possibilities for slowing or preventing Type 1 diabetes. Rather than thinking of B cells as acting in just one way, scientists can now develop strategies that address both mechanisms—stopping B cell activation of T cells and protecting regulatory T cells from interference.

Dr. Moore noted that this discovery may not be unique to Type 1 diabetes. "We believe this may be an important, unrecognized part of immune regulation that may be at work in other autoimmune disorders," he said. This suggests the research could eventually benefit people with other autoimmune conditions as well.

The Vanderbilt team plans to use these insights to develop new approaches for preserving beta cells and delaying or preventing Type 1 diabetes. The findings also invite other researchers to investigate whether similar B cell and Treg interactions occur in other autoimmune diseases, potentially broadening the impact of this work.

Origin: eurekalert.org (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.